Heron Therapeutics (NASDAQ:HRTX – Get Free Report) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports. Needham & Company LLC lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Get Heron Therapeutics alerts:Read Our Latest Stock Analysis on HRTXHeron Therapeutics Stock PerformanceNASDAQ HRTX opened at $0.51 on Monday. Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. Recommended StoriesReceive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.